Amphastar Pharmaceuticals (AMPH) Revenue (2013 - 2026)

Amphastar Pharmaceuticals has reported Revenue for 14 years, with the latest figure at $183.9 million in Q2 2026.

• On a quarterly basis, Revenue rose 5.44% year-over-year to $183.9 million in Q2 2026; TTM through Jun 2026 was $730.0 million, a 1.02% increase from a year earlier, with the FY2025 full-year figure at $719.9 million, down 1.65% from the prior year.
• Revenue was $183.9 million for Q2 2026 at Amphastar Pharmaceuticals, up from $171.2 million in the prior quarter.
• The five-year high for Revenue was $191.8 million in Q3 2025, with the low at $120.1 million in Q3 2022.
• Average Revenue over 5 years is $163.9 million, with a median of $173.1 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Revenue jumped 50.3% in 2023, then slipped 4.38% in 2025.
• Over 5 years, Revenue stood at $135.0 million in 2022, then jumped by 31.91% to $178.1 million in 2023, then rose by 4.73% to $186.5 million in 2024, then slipped by 1.83% to $183.1 million in 2025, then grew by 0.44% to $183.9 million in 2026.
• The last three Revenue figures came in at $183.9 million (Q2 2026), $171.2 million (Q1 2026), and $183.1 million (Q4 2025), per Business Quant data.